The purpose of SMA Europe is to provide a framework to stimulate collaboration and accelerate translational research pathways in SMA and promote patient care.

  1. Novartis has acquired AveXis

    Novartis has acquired AveXisIn April this year, we heard that talks were ongoing regarding a proposed acquisition of AveXis by Novartis. We have now been informed that this has happened so as that AveXis is now officially a Novartis company.

    AveXis has provided us with a community update, stating that the company remains steadfastly dedicated to the SMA community. They are excited about the promise of the future as a part of this organisation and hope to accelerate their mission of bringing AVXS‐101 to people with SMA as quickly and safely as possible.

    For more information